Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293
- 1 June 1996
- journal article
- research article
- Published by Springer Science and Business Media LLC in Medical Oncology
- Vol. 13 (2), 87-93
- https://doi.org/10.1007/bf02993858
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT)Investigational New Drugs, 1995
- Docetaxel: an Active New Drug for Treatment of Advanced Epithelial Ovarian CancerJNCI Journal of the National Cancer Institute, 1995
- Activity of Taxol in Patients With Squamous Cell Carcinoma and Adenocarcinoma of the EsophagusJNCI Journal of the National Cancer Institute, 1994
- Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: Reversibility, ligand stoichiometry, and competitionBiochemistry, 1993
- Phase I Trial of Taxotere: Five-Day ScheduleJNCI Journal of the National Cancer Institute, 1992
- Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and-resistant human ovarian carcinoma cell linesCancer Chemotherapy and Pharmacology, 1992
- Relationships between the structure of taxol analogs and their antimitotic activityJournal of Medicinal Chemistry, 1991
- Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of TaxolJNCI Journal of the National Cancer Institute, 1991
- Chemotherapy of gastric cancerCancer Treatment Reviews, 1988
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958